Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Vivos Therapeutics (VVOS) Long-Term Debt Repayments (2021)

Vivos Therapeutics (VVOS) reported Long-Term Debt Repayments of $25000.0 for Q1 2021.

Vivos Therapeutics (VVOS) has 1 years of Long-Term Debt Repayments data on file, last reported at $25000.0 in Q1 2021.

  • Quarterly Long-Term Debt Repayments changed N/A year-over-year to $25000.0 in Q1 2021, while the trailing twelve-month figure through Dec 2021 was $25000.0 (changed N/A YoY) and the FY2021 annual result came in at $25000.0, down 66.67% from the prior year.
  • Long-Term Debt Repayments held at $25000.0 in Q1 2021 per VVOS's latest filing.
  • Across five years, Long-Term Debt Repayments topped out at $25000.0 in Q1 2021 and bottomed at $25000.0 in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.42 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.00 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Vivos Therapeutics 9.87 Mn 7.64 Mn 3.06 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2021 25,000.00
Mar 31, 2021 25,000.00